Callisto Pharmaceuticals announced a few weeks back that they're feeling pretty good about Guanilib. So good, in fact, that they intend to move the drug into clinical trials in ulcerative colitis. They announced that they have new animal data that suggest that taking Guanilib orally reduces gastrointestinal (GI) inflammation.
"These are important findings and suggest a possible mechanism of action of Guanilib and implicate its therapeutic potential in GI inflammatory diseases such as IBD and IBS," said Dr. Kunwar Shailubhai, Senior Vice President, Discovery Research of Callisto.
Link to Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
del.icio.us tags:
Ulcerative Colitis